Amgen Inc., a leading biotechnology company, has been making headlines in recent days.The stock price of AMGN on Nasdaq has seen some fluctuations, with the open price of $279.00 and a day range of $278.00 - $282.69. The 52-week range for the stock is $257.80 - $346.85. The current market cap of the company stands at $150.51 billion, with 537.53 million shares outstanding and a public float of 536.14 million shares.
Looking at the financial performance of Amgen Inc., the company has reported an EPS (TTM) of $7.81, with a P/E ratio (TTM) of 37.64. The dividend yield is 3.06%, with the latest dividend declared at $2.25. The ex-dividend date is set for November 18, 2024.
Amgen Inc. has been making news with its latest developments in the field of biotechnology. The company's stock quote and historical data can be found on various platforms, providing investors with vital information for trading and investing.
One recent news headline highlights the stock decline of Amgen Inc. due to safety concerns about its GLP-1 candidate MariTide. The management and analysts of Amgen downplayed the bone safety concerns, but the stock still dropped nearly 15% last week.
Amgen Inc. is listed on NASDAQ under the ticker symbol AMGN, with a current stock price per share of approximately $280.07. The stock has a 65-day average volume of 2,248,928 shares.
In another news article, it is mentioned that the current stock price for Amgen (NASDAQ: AMGN) is $280.25 as of November 27, 2024. This information provides investors with the latest updates on the stock price.
Aside from stock-related news, Amgen Inc. has also made press releases to provide insights on the company's activities and corporate news. These press releases can be valuable for traders and investors in making informed decisions.
In terms of shareholder activity, Northwest & Ethical Investments L.P. decreased its holdings in shares of Amgen Inc. by 15.5% in the third quarter. This indicates an interesting trend in ownership of AMGN stock.
Analyzing the overall market sentiment towards Amgen Inc., analysts have mixed opinions. Some analyst reports mention safety concerns about MariTide, while others emphasize the promising weight loss results in Phase II for type 2 diabetes. Investors should carefully consider these factors before making any investment decisions.
Overall, Amgen Inc.'s stock price has experienced fluctuations based on recent developments and market trends. It is important for investors to stay updated with the latest news and analysis to make informed decisions regarding AMGN stock.
